Celator Pharmaceuticals Corp.
Celator Pharmaceuticals Corp., a prominent player in the biopharmaceutical industry, is headquartered in California. Founded in 2000, the company has made significant strides in developing innovative cancer therapies, particularly through its proprietary technology, the CombiPlex® platform. This unique approach enhances the efficacy of existing treatments, setting Celator apart in a competitive market. With a focus on improving patient outcomes, Celator's core products include the FDA-approved Vyxeos™ (CPX-351), a novel chemotherapy formulation for acute myeloid leukaemia. The company has garnered recognition for its commitment to advancing cancer care, positioning itself as a leader in the oncology sector. Through strategic partnerships and a robust pipeline, Celator Pharmaceuticals continues to drive innovation and improve the lives of patients worldwide.
DitchCarbon Score
How does Celator Pharmaceuticals Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celator Pharmaceuticals Corp.'s score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celator Pharmaceuticals Corp., headquartered in California, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Jazz Pharmaceuticals plc, which may influence its climate commitments and reporting practices. As of now, Celator Pharmaceuticals has not established any documented reduction targets or initiatives related to carbon emissions. The absence of specific targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Jazz Pharmaceuticals, emissions data and climate initiatives may be cascaded from this parent company. However, no specific emissions data or reduction targets from Jazz Pharmaceuticals plc have been provided in this context. In summary, while Celator Pharmaceuticals Corp. is part of a larger corporate family that may have climate commitments, it currently lacks specific emissions data and reduction initiatives of its own.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Celator Pharmaceuticals Corp. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
